GlassScriptPhysician profile
Thomas M Rogers
NPI 1588983589
$1,907.81
in general payments reported to CMS, 2019-2025
30 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $76.42 · 2021: $423 · 2022: $62.61 · 2023: $31.54 · 2024: $217 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.76 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $457.47 | 2024-2025 | |
| Biogen, INC. | $339.11 | 2019-2025 | Tysabri, Spinraza, Qalsody |
| Alexion Pharmaceuticals, INC. | $208.31 | 2019-2025 | Ultomiris |
| Abbvie INC. | $196.18 | 2019-2025 | |
| Amgen INC. | $67.49 | 2019-2024 | Uplizna |
| Genentech USA, INC. | $55.10 | 2019-2023 | Ocrevus |
| Janssen Pharmaceuticals, INC | $53.40 | 2021-2022 | |
| Argenx US, INC. | $49.78 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Novartis Pharmaceuticals Corporation | $33.10 | 2019 | |
| Ucb, INC. | $32.44 | 2019 | |
| Eisai INC. | $32.23 | 2019 | |
| Lilly USA, LLC | $28.19 | 2019-2023 | Reyvow, Emgality |
| Lundbeck LLC | $27.31 | 2019-2020 | |
| Livanova USA, INC. | $26.42 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $25.55 | 2025 | Dysport |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24.50 | 2025 | |
| Kyowa Kirin, INC. | $23.59 | 2020 | |
| Sunovion Pharmaceuticals INC. | $23.04 | 2020 | |
| Abbott Laboratories | $21.49 | 2024 | Infinity |
| Biomarin Pharmaceutical INC. | $19.37 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $18.89 | 2024 | |
| Neurocrine Biosciences, INC. | $17.82 | 2024 | Ingrezza |
| Emd Serono, INC. | $17.61 | 2025 | |
| Philips North America LLC | $16.74 | 2024 | (7999) Src Undivided |
| Tanabe Pharma America, INC. | $16.34 | 2019 | |
| Allergan, INC. | $16.07 | 2021 | |
| Mdd US Operations, LLC | $16.05 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.88 | 2019 | |
| Celgene Corporation | $14.73 | 2021 | |
| Axsome Therapeutics, INC. | $14.61 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.